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Bariatric surgery is an increasingly common option for control of type 2 diabetes (T2D) and obesity. 
Mechanisms underlying rapid improvement of T2D after different types of bariatric surgery are not 
clear. Caloric deprivation and altered levels of non-esterified fatty acid (NEFA) have been proposed. 
This study examines how sleeve gastrectomy (SG), Roux-en-Y gastric bypass (GBP) or matched 
hypocaloric diet (DT) achieves improvements in T2D by characterising components of the glucose 
metabolism and NEFA levels before and 3 days after each intervention.   
 
Methods: 
Plasma samples at 5 time points during oral glucose tolerance test (OGTT) from subjects with T2D 
undergoing GBP (N = 11) or SG (N = 12) were analysed for C-peptide, insulin and glucose before surgery 
and 3 days post intervention or after DT (N=5). Fasting palmitic, linoleic, oleic and stearic acid were 




Subjects who underwent GBP surgery experienced the greatest improvement in glycaemia (median 
reduction in BG from basal by 29% [IQR -57, -18]) and greatest reduction in all NEFA measured. SG 
achieved improvement in glycaemia with lower ISR and reduction in all but palmitoleic acid.  DT 




GBP, SG and DT each improve glucose metabolism through different effects on pancreatic beta cell 





Bariatric surgery is an increasingly common and effective therapeutic option for control of type 2 
diabetes (T2D) and obesity [1, 2]. Rapid improvement of fasting glucose, insulin secretion and insulin 
resistance has been reported within days of Roux-en-Y gastric bypass (GBP) [3-5] and sleeve 
gastrectomy (SG) [6, 7]. Hypocaloric dieting has also been shown to restore normal glucose levels [8, 
9]. Although the precise mechanisms underlying such early diabetes remission are not known, caloric 
deprivation and decreased levels of non-esterified fatty acid (NEFA) have been proposed [10].  
NEFA levels are commonly elevated in those suffering from obesity and T2D [11, 12] due to increased 
fat mass and cell size in both subcutaneous and intra-abdominal fat tissues and excessive lipolysis in 
adipose tissues [13]. Chronically elevated plasma NEFA have been shown to contribute to β-cell 
dysfunction in T2D [14-16]. Furthermore, studies indicate that elevated plasma NEFA may directly 
contribute to the advance of insulin resistance both in the periphery and the liver [17, 18].  
Among obese patients with T2D, all three treatments: SG, GBP or hypocaloric diet are known to 
improve glycaemia [8, 9, 19]. Bariatric surgery has also been shown to decrease NEFA concentrations 
within one week after intervention [10].  This is  consistent with the anti-lipolytic effect of insulin that 
lowers plasma NEFA by inhibiting the release of fatty acid from adipose tissue [20].  However, short 
term exposure to very low calorie diet has been shown to increase plasma NEFA [9, 21, 22]. The aim 
of this study was to examine how each treatment (SG, GBP or matched hypocaloric diet) achieves 
improvements in glycaemia by characterising the different components of glucose metabolism and 
levels of non-esterified fatty acids (NEFAs) before and 3 days after each intervention.  This study 
investigates the acute effects of surgery and matched surgical diet at 3 days to avoid confounding 
effects of weight loss and also to avoid difficulties of maintaining such matched surgical diet longer 







Patients with T2D scheduled for either laparoscopic GBP or SG in three different hospitals in the 
Auckland region (Auckland City Hospital, North Shore Hospital and Middlemore Hospital) between 
August 2010 and March 2012 were recruited for the study. Patients on the waiting list for bariatric 
surgery were recruited to the matched surgical diet (DT) group. Patients with T2D, between 18 and 50 
years of age, were eligible for the study if BMI was at least 35 kg/m2. Patients receiving insulin therapy, 
incretin hormone-based therapy or diet controlled T2D were excluded. Table 1 summarises the 
subject characteristics. Informed consent was obtained from all individual participants included in the 
study. 
 All subjects consented to have a 75 g oral glucose tolerance test (OGTT) the day before and at 3 days 
after each intervention.  All patients had oral glucose lowering medications withheld from the night 
prior to each baseline OGTT until at least their second OGTT, or longer in those who received surgery.  
Those in the DT control group were asked to undergo equivalent caloric intake as patients in the 
surgical group for 3 days of observation, including fasting overnight prior to another 24 h of fasting 
(sips of water only) followed by free oral fluids and three servings of Optifast® on the second and third 
days. All participants were asked to keep a diary of their oral intake.  
Those who participated in the DT arm of the study were invited to take part again when they were 
scheduled for either GBP or SG surgery, provided this occurred at least 2 weeks after their DT 
measurements. This minimum 2-week washout period was to ensure that the caloric-matched control 
intervention did not increase the optimisation of such surgical patients, beyond the routine pre-
surgical optimisation with Optifast® diet for 3 weeks. This study was approved by local ethics 




Table 1: Summary of subject characteristic. Data shown as median [IQR] where appropriate. 
 Matched caloric 




Gastric Bypass Surgery 
(GBP) 
N 5 11 11 
Age (years) 45 [39 53]  45 [43 49] 41 [38 46] 
Gender (M/F) 2/3 3/8 1/10 
BMI (kg/m2) 47.8 [38 50]  42.2 [40 48] 44.5 [40 49] 
HbAIc (mmol/mol) 57 [55 67] 45 [45 66] 53 [51 64] 
Duration of Diabetes (years)  2 [2 3] 3 [2 4] 4 [1.5 5] 
 
Surgical Protocol  
Patients scheduled for either laparoscopic GBP or SG were prescribed a hypocaloric diet with three 
servings of Optifast® (152 cal) plus vegetables daily during the 3 weeks prior to surgery. All patients 
fasted from midnight before surgery. The GBP involved a 100 cm antecolic Roux limb with hand sewn 
pouch-jejunostomy, a 60 cm biliopancreatic limb and a hand sewn small bowel anastomosis. The SG 
involved a longitudinal resection of the stomach against a 32 French bougie from just lateral to the 
angle to His to 2 cm proximal to the pylorus. Post-operative intravenous fluids with Plasmalyte® were 
administered until oral fluid intake was 1 L per day (approximately 48 h). Sips of water occurred on 
day 1, followed by free oral fluids from day 2 with clear soups, low fat smoothies or Optifast® very low 
calorie diet. 
OGTT and NEFA’s  
Plasma samples for glucose, C-peptide and insulin were collected at 0, 30, 60, 90 and 120 min after 
ingestion of 75 g oral glucose (dissolved in 75 mL water). Glucose was measured by autoanalyzer 
(Hitachi High Technologies Corporation).  Insulin and C-peptide were measured using the Human 
Metabolic Hormone Panel (Milliplex, Millipore, MA, USA).  Five NEFAs in plasma, including Palmitic, 
Stearic, Oleic, Palmitoleic and Linoleic acid, were measured using an Agilent 6420 triple quadrupole 
LC-MS/MS system with margaric acid added in the samples as an internal standard. Chromatographic 
separation was achieve by using a VisionHT C18, 3 µm, 2.1X50 mm column (Grace Davidson, Auckland, 
NZ) with guard. MS2 single ion monitoring (SIM) was set at 253, 255, 269, 279, 281,283 corresponding 
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to palmitoleic, palmitic, margaric, linoleic, oleic and stearic acid, respectively, to detect and measure 
the five NEFAs and the internal standard.    
Analysis  
C-peptide measurements taken every 30mins during the course of the OGTT were used to model 
subject-specific insulin secretion using deconvolution [23]. Kinetic parameters were based on the 
subject’s age and population parameters for T2D subjects.  
To assess the change in response to the OGTT for each patient, the change in area above basal was 
calculated for each metric. Area above basal is the area between the measured basal value (t = 0) and 
the measured blood glucose (BG), measured plasma insulin (PI), and estimated subject-specific insulin 
secretion rate (ISR) profile over the course of the OGTT. These areas are shown in Figure 1. The 
percentage change was calculated as the post-intervention area above basal subtracted from the pre-
intervention area above basal and divided by the pre-intervention area above basal. Thus, a negative 
change in the BG area above basal represents a better uptake of the 75g glucose load given in the 
OGTT. The per-subject percentage change and the median and interquartile range (IQR) was 




Figure 1: Example displaying the areas above basal for blood glucose (red), Plasma Insulin (green) and Insulin Secretion (blue) 
for a subject’s response to an OGTT 
 
Results  
The majority of subjects experienced an improvement in their glycaemic response to an OGTT test 
after the intervention (3/5 DT, 9/11 SG and 9/11 GBP patients showed glycaemic improvement). 
Overall, subjects who underwent GBP or SG surgery experienced significant improvement in glycaemia 
with a median reduction of BG above basal of -29% [IQR -57, -18] after GBP and -19% [IQR -41,-7.3] 
after SG, as seen in Table 2. DT subjects experienced a non-significant BG reduction although all 
stopped their oral glucose lowering therapy during the acute period of observation.  The DT patients 
achieved a lack of glucose deterioration through an increase in ISR, 105% [IQR, 20, 220] while the SG 
and GBP subjects displayed no significant change in ISR. SG experienced decreased plasma insulin 
above basal area while GBP and DT subjects did not have significant change in their plasma insulin.   




















































































Insulin sensitivity estimated by HOMA-IR did not change significantly among any of the 3 groups as 
show in column 5 of Table 2. 
The 5 GBP and 5 SG subjects in quadrant C of Figure 3 improved glycaemia with decreased ISR above 
basal area, indicating greater insulin sensitivity. The 4 GBP, 4 SG and 3 DT subjects in quadrant A 
improved glycaemia with an increased ISR indicating improved beta cell function. In contrast, the 2 SG 
subjects in quadrant D had a worse glycaemic response with decreased ISR indicating decreased beta 
cell function. Finally, the 2 GBP and 2 DT subjects in quadrant B had a worse glycaemic response 
despite increased ISR, indicating reduced sensitivity.  
In Figure 4 quadrant C, 7 SG, 5 GBP and 2 DT achieved an improvement in glycaemia with a decrease 
in PI indicating improved uptake of glucose. The 2 SG, 4 GBP and 1 DT in quadrant A had improved 
glycaemia and increased PI indicating a greater improvement in sensitivity, especially for GBP subjects 
29 and 08 who also reduced their ISR above basal area. Quadrant D contains 2 SG and 1 GBP subjects 
who had reduced PI and worse glycaemic response, indicating increased insulin losses to kidneys and 
liver for GBP 19 who had increased ISR area above basal. Quadrant B represents those who have 
increased PI and worse glycaemic response, indicating increased insulin resistance especially as all 
subjects in this quadrant have increased ISR above basal area. 
Figure 2 highlights the overall percentage change in the basal NEFA’s measured before and 3 days 
after each intervention. Subjects in all three intervention groups experienced a significant decrease in 
palmitic acid.  In addition, those who underwent GBP surgery also experienced a significant reduction 







  Table 2: Summary per patient of diabetes medications pre-intervention and %change in above basal areas of BG, ISR and 



















above Basal for 
PI 
DT 11 2  -78.49 15.38 197.93 140.70 
DT 12 2  115.96 -47.66 16.48 -23.76 
DT 16 2 20 -0.26 -25.13 105.25 112.36 
DT 17 2  -38.55 46.37 20.82 20.55 
DT 20 2  -58.15 -38.07 280.55 -37.00 
Median 
[IQR] 
 2 [2 2] n/a -38.6 [-68 58] -25.1 [-41  23] 105 [20 220]* 20.5 [-27  120] 
        
SG 3 2  -69.08 -42.60 -72.64 -40.54 
SG 4 2 10 -55.73 -10.41 87.55 135.52 
SG 12 2  63.72 -46.04 14.62 -41.28 
SG 23 1.5 10 -54.26 -19.04 14.64 79.64 
SG 24 1  -36.33 59.89 -79.37 -16.56 
SG 26 0  58.49 -36.79 -3.48 -27.12 
SG 27 2.55 10 -77.83 166.83 -46.52 -6.70 
SG 30 1.5  126.06 -30.70 -30.49 -26.31 
SG 34 0 10 171.98 -47.18 -23.03 -39.38 
SG 35 3  -1.13 -6.29 2.27 -26.82 
SG 36 3  -29.10 -11.98 -7.46 -27.93 
Median 
[IQR] 
 2 [ 1.1  2.4] n/a -29.1 [-56 64] -19.0 [-41  -
7.3]* 
-7.50 [-43  12] -26.8 [ -37  -
9.2]* 
        
GBP 2 1  15.62 -47.56 -34.16 -1.05 
GBP 8 3  179.05 -63.66 -35.53 24.65 
GBP 13 2 5 -74.33 -22.61 107.80 -27.81 
GBP 19 1  -80.88 52.63 21.97 -202.30 
GBP 21 1  55.68 47.12 30.66 38.76 
GBP 29 2.55  417.91 -96.49 -2.65 92.50 
GBP 33 2  -39.51 -33.27 6.49 -11.06 
GBP 38 3  -81.25 -17.21 -12.64 -44.33 
GBP 39 3  29.27 -29.95 70.95 13.30 
GBP 40 3 480 10.55 -60.00 72.93 94.82 
GBP 41 2  28.47 -21.53 -51.24 -47.34 
Median 
[IQR] 
 2 [1.3  3] n/a 15.6 [-74 56] -29.4 [-57  -
18]* 










Figure 2: Over all cohort percentage change in basal NEFA's measured pre and 3 day post intervention. Data shown as median 







































Figure 3: % Change in area above basal BG vs. ISR.  Quadrants A, B, C and D highlight the different responses of each subject. 
Those in quadrant C have achieved an improvement in glycaemia with a decrease in ISR indicating greater insulin sensitivity. 
Quadrant A represents those who have achieved an improvement in glycaemic with an increase in insulin secretion indicating 
improved beta cell function. D represents those who have reduced their ISR and have had a worse glycaemic response 
indicating decreased beta cell function. B represents those who have increased ISR and have had a worse glycaemic response 
indicating reduced sensitivity.  






































































Figure 4: % Change in area above basal BG vs. PI. Quadrants A, B, C and D highlight the different responses of each subject. 
Those in quadrant C have achieved an improvement in glycaemia with a decrease in PI indicating improved uptake of glucose. 
Quadrant A represents those who have achieved an improvement in glycaemic with an increase in PI indicating an 
improvement in sensitivity if ISR has reduced. D represents those who have reduced their PI and have had a worse glycaemic 
response indicating increased insulin losses to kidneys and liver if ISR has increased. B represents those who have increased 
PI and have had a worse glycaemic response indicating increased resistance.  
 
Discussion  
 The two surgical treatments (SG and GBP), but not matched DT, provided significant improvements 
in glycaemia among patients with T2D controlled with oral agents.  Greater extent of glycaemic 
improvement was seen after GBP than after SG.  DT patients achieved lack of glucose deterioration 
despite stopping their oral glucose lowering therapy by increasing ISR.  ISR was unchanged after SG 
and GBP, but patients following SG had significantly decreased plasma insulin.   
Increasing insulin secretion rate is not thought to be the most sustainable method for achieving 
glycaemic control due to beta-cell exhaustion, and combined with the fact that it is difficult to sustain 
such dramatic caloric restriction for a prolonged length of time. However, reducing NEFA levels is likely 


































































to be a more sustainable method for achieving glycaemic control as chronically elevated plasma NEFA 
have been shown to contribute to β-cell dysfunction in T2D [14-16]. Furthermore, studies indicate that 
elevated plasma NEFA may directly contribute to the advance of insulin resistance both in the 
periphery and the liver [17, 18] .  These reasons are likely why long term diabetes remission after diet 
(and to a less extent after SG [24, 25]) is less than that achieved by GBP.   
Assessing beta-cell function is problematic because insulin secretion by beta-cells is adaptive to 
chronic stimuli, such as weight changes and acute challenges such as fasting and feeding.  The 
secretory indexes that reflect long-term adaptation from those that result from the dynamic 
behaviour of the beta cell are basal insulin secretion and total insulin output versus beta-cell glucose 
sensitivity (the slope of the insulin secretion/plasma glucose dose response relationship) which is the 
ability to control glycaemia by promptly releasing sufficient insulin.  This key function is what we have 
captured in the %Change area above Basal for ISR derived from OGTT as we capture the total insulin 
secretion in response to a glucose challenge and its change acutely after the intervention before the 
long-term weight loss related effects have taken place.  %Change above basal refers to the additional 
amount of insulin secreted in response to the oral glucose load beyond the basal level.  
Other studies reporting changes in beta cell function with bariatric surgery show that fasting insulin 
concentrations or secretion rates and total insulin output in response to oral glucose are all found to 
decrease after most types of bariatric surgery [26-29]. This change is attributed to reduced adipose 
mass and improved insulin sensitivity. AIR and insulinogenic index after GBP have been shown to 
progressively improve over time, paralleling ongoing weight loss. What the results from this study add, 
is the comparative change in insulin secretion leading to better glycaemic response as early as 3 days 
after GBP, SG and matched caloric restriction, when there has been little change in adipose mass.   
Bariatric surgery is reported to improve the insulin sensitivity in obese patients with T2D by up to 50% 
in the first 6 weeks when only a small reduction in BMI has occurred, of around 10% [30]. 
Subsequently, after four months, when BMI has dropped by around 30%, insulin sensitivity does not 
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improve by much more.  This has been attributed to the fact that early after surgery, caloric restriction 
plays a major role in improving insulin sensitivity.  Months to years after surgery, once weight loss has 
stabilised, then a quantitative relationship between the changes in BMI and insulin sensitivity is 
evident. It is not clear whether there is a greater insulin sensitising power of GBP than SG, although 
biliopancreatic diversions have been shown to be the most effective in this regard [30]. While HOMA-
IR did not significantly alter acutely after any of the three interventions, this may have been masked 
by the withdrawal of metformin therapy, an insulin sensitising medication.   
An explanation for those not seeing improvement, quadrants B and D in Figure 2 and 3, can be found 
in the trade-off between plasma insulin, insulin secretory rate and BG. Subjects who increase their ISR 
may also increase their plasma insulin proportionally – highlighting that while more is being secreted 
it is failing to be used in the uptake of glucose to cells.   DT subjects 11 and 17, and GBP subject 21, all 
display this reduced uptake of glucose and increase in glycaemic response.  In addition, all but two 
subjects were on metformin and several were also using sulfonylureas pre-operatively (SG 26 and 34). 
These drugs were not removed from the participants until midnight before the first OGTT test. Thus, 
those patients who have not improved (quadrants B and D of Figures 2 and 3) have not been able to 
achieve the same level of glycaemic control as with their medications, not that they do not possibly 
have some small improvement from the glycaemic response they would achieve without medication 
or intervention.  
Limitations  
The main limitation of this study is the low cohort numbers especially within the DT group. It is difficult 
to obtain significant trends in a small data set. However, this initial proof of concept investigation has 
shown that it is worth pursuing this avenue of investigation. A larger cohort study is the next step to 
proving that the patterns underlying improvement in glycaemia are specific to each type of 
intervention and assessing the variability in mechanisms involved.  Whether this will be able to assist 
in determining the most appropriate therapy and/or the risk of failure to respond for patients with 
different underlying glucose abnormalities is yet to be demonstrated.   
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One of the difficulties with defining the best treatment for different patients, is the lack of accurate 
phenotyping of patients with T2D.  Even duration of diabetes is dependent on the screening practice 
for T2D and degree of patient concern around presentation with minor osmotic symptoms, leading to 
variable delays in diagnosis.  While triglycerides and total cholesterol, HDL and LDL cholesterol are 
measured as part of cardiovascular risk profiling, NEFAs are currently not measured in routine clinical 
practice. Fasting insulin, C-peptide and OGTTs are also not frequent in routine clinical practice. 
Another limitation is the fact that patients were on their diabetes medication up until midnight before 
the first OGTT results. This makes it difficult to gauge the improvement of those non-responsive 
patients. It is unknown what residual metformin effects are acting on each individual and it is likely 
that two patients with the same levels of metformin will have different outcome effects on glucose 
metabolism. However, the trends found are still valid as long as one considers no improvement a 
success as the subject is able to respond without the aid of medication in the same way as when using 
medication.   
The third limitation is the infrequent sampling interval of C-peptide. Sampling every 30 minutes 
provides a good indication using Van Cauter et al. [23] deconvolution method of the insulin secreted 
but more frequent sampling ~15mins would provide a much more accurate approximation of the 
insulin secretion levels.  
 Finally, the short interval of three days post-surgery was selected to avoid confounding effects of 
weight loss and also to avoid difficulties of maintaining such matched surgical diet longer term in 
patients not having surgery.  Following the acute stress response to surgery, these patients may not 
have recovered to steady-state, however, continuous glucose measurements of these patients taken 
preoperatively, indicate return of glycaemic fluctuations to pre-operative levels from 24 hours after 




 Conclusion  
 GBP achieves the largest improvement in glycaemia which may be linked to its success in reducing 
both linoleic and palmitic NEFA concentrations.  SG achieves significant improvement in glycaemia 
with lower plasma insulin increasing the effectiveness of the insulin secreted.  While DT did not 
achieve significant improvement in glycaemia, it was associated with a significant increase in ISR. 
These results indicate that GBP, SG and DT each improve glucose metabolism through different effects 
on pancreatic beta cell function, insulin sensitivity and free fatty acids. However, it is important to 
note that C-peptide, insulin and glucose levels measured so soon after SG or GBP surgery do not 
necessarily indicate the extent of diabetes remission long term.  
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Figure Legend  
Figure 5: Example displaying the areas above basal for blood glucose (red), Plasma Insulin (green) and 
Insulin Secretion (blue) for a subject’s response to an OGTT 
Figure 6: Over all cohort percentage change in basal NEFA's measured pre and 3 day post intervention. 
Data shown as median [IQR] where appropriate. 
Figure 7: % Change in area above basal BG vs. ISR.  Quadrants A, B, C and D highlight the different 
responses of each subject. Those in quadrant C have achieved an improvement in glycaemia with a 
decrease in ISR indicating greater insulin sensitivity. Quadrant A represents those who have achieved 
an improvement in glycaemic with an increase in insulin secretion indicating improved beta cell 
function. D represents those who have reduced their ISR and have had a worse glycaemic response 
indicating decreased beta cell function. B represents those who have increased ISR and have had a 
worse glycaemic response indicating reduced sensitivity.  
Figure 8: % Change in area above basal BG vs. PI. Quadrants A, B, C and D highlight the different 
responses of each subject. Those in quadrant C have achieved an improvement in glycaemia with a 
decrease in PI indicating improved uptake of glucose. Quadrant A represents those who have achieved 
an improvement in glycaemic with an increase in PI indicating an improvement in sensitivity if ISR has 
reduced. D represents those who have reduced their PI and have had a worse glycaemic response 
indicating increased insulin losses to kidneys and liver if ISR has increased. B represents those who 





Table List  
Table 3: Summary of subject characteristic. Data shown as median [IQR] where appropriate. 
 Matched caloric 




Gastric Bypass Surgery 
(GBP) 
N 5 11 11 
Age (years) 45 [39 53]  45 [43 49] 41 [38 46] 
Gender (M/F) 2/3 3/8 1/10 
BMI (kg/m2) 47.8 [38 50]  42.2 [40 48] 44.5 [40 49] 
HbAIc (mmol/mol) 57 [55 67] 45 [45 66] 53 [51 64] 

























  Table 4: Summary per patient of diabetes medications pre-intervention and %change in above basal areas of BG, ISR and 



















above Basal for 
PI 
DT 11 2  -78.49 15.38 197.93 140.70 
DT 12 2  115.96 -47.66 16.48 -23.76 
DT 16 2 20 -0.26 -25.13 105.25 112.36 
DT 17 2  -38.55 46.37 20.82 20.55 
DT 20 2  -58.15 -38.07 280.55 -37.00 
Median 
[IQR] 
 2 [2 2] n/a -38.6 [-68 58] -25.1 [-41  23] 105 [20 220]* 20.5 [-27  120] 
        
SG 3 2  -69.08 -42.60 -72.64 -40.54 
SG 4 2 10 -55.73 -10.41 87.55 135.52 
SG 12 2  63.72 -46.04 14.62 -41.28 
SG 23 1.5 10 -54.26 -19.04 14.64 79.64 
SG 24 1  -36.33 59.89 -79.37 -16.56 
SG 26 0  58.49 -36.79 -3.48 -27.12 
SG 27 2.55 10 -77.83 166.83 -46.52 -6.70 
SG 30 1.5  126.06 -30.70 -30.49 -26.31 
SG 34 0 10 171.98 -47.18 -23.03 -39.38 
SG 35 3  -1.13 -6.29 2.27 -26.82 
SG 36 3  -29.10 -11.98 -7.46 -27.93 
Median 
[IQR] 
 2 [ 1.1  2.4] n/a -29.1 [-56 64] -19.0 [-41  -
7.3]* 
-7.50 [-43  12] -26.8 [ -37  -
9.2]* 
        
GBP 2 1  15.62 -47.56 -34.16 -1.05 
GBP 8 3  179.05 -63.66 -35.53 24.65 
GBP 13 2 5 -74.33 -22.61 107.80 -27.81 
GBP 19 1  -80.88 52.63 21.97 -202.30 
GBP 21 1  55.68 47.12 30.66 38.76 
GBP 29 2.55  417.91 -96.49 -2.65 92.50 
GBP 33 2  -39.51 -33.27 6.49 -11.06 
GBP 38 3  -81.25 -17.21 -12.64 -44.33 
GBP 39 3  29.27 -29.95 70.95 13.30 
GBP 40 3 480 10.55 -60.00 72.93 94.82 
GBP 41 2  28.47 -21.53 -51.24 -47.34 
Median 
[IQR] 
 2 [1.3  3] n/a 15.6 [-74 56] -29.4 [-57  -
18]* 
6.49 [-29  61] -1.05 [-40  35] 
 
